Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.
Key Financial Performance
Cash Balance As of September 30, 2025, the cash balance was approximately $86 million. This is not compared year-over-year, but it is noted that subsequent to the quarter, approximately 0.8 million shares were sold through the company's ATM facility, contributing to net proceeds of approximately $1.6 million.
Revenues Revenues for the third quarter of 2025 were approximately $1.9 million, compared to approximately $17.1 million for the same period in 2024. This significant decrease is attributed to the recognition of respective portions of both the upfront payment and the IND milestone payment from the license agreement with Gilead in the prior year.
R&D Expenses R&D expenses for the third quarter of 2025 were approximately $5.8 million, compared to approximately $6.3 million in the third quarter of 2024. This represents a slight decrease, which aligns with the company's planned expenditures.
G&A Expenses G&A expenses for the third quarter of 2025 were approximately $2.2 million, compared to approximately $2.6 million for the same period in 2024. This decrease reflects cost management efforts.
Net Loss For the third quarter of 2025, the net loss was approximately $6.98 million or $0.07 per basic and diluted share, compared to a net profit of approximately $1.28 million or $0.01 per basic and diluted share in the third quarter of 2024. The shift from profit to loss is primarily due to the significant decrease in revenues.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Fc reduced anti-TIGIT programs: COM902 is one of the only 2 clinical stage Fc reduced anti-TIGIT monoclonal antibodies currently in clinical development. Positive Phase III data from Arcus/Gilead with the only other known Fc reduced anti-TIGIT monoclonal antibody is expected in 2026 and could be a real catalyst for COM902.
Rilvegostomig: AstraZeneca's Fc reduced anti-PD-1 TIGIT bispecific with the TIGIT component derived from COM902. AstraZeneca estimates nonrisk-adjusted peak year revenue target of more than $5 billion. Broad development program spans 11 Phase III trials across various cancers.
COM701: Fully owned Fc reduced monoclonal anti-PVRIG antibody in the clinic. Positive data in ongoing MAIA-ovarian platform trial could support broader clinical development for platinum-sensitive ovarian cancer.
GS-0321: Potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. Represents a novel antibody approach for cancer treatment. Compugen eligible for $758 million in milestone payments and single-digit to low double-digit tiered royalties.
AstraZeneca partnership: Potential commercial opportunity for Rilvegostomig with AstraZeneca estimating over $5 billion in peak year revenue. Broad development program across multiple cancers.
Gilead partnership: GS-0321 program provides potential for over $1 billion in milestone payments plus royalties.
Cash position: As of September 30, 2025, approximately $86 million in cash, cash equivalents, and investments. Cash runway expected to fund operations into Q3 2027.
Revenue: Third quarter 2025 revenue was $1.9 million, compared to $17.1 million in the same period in 2024, reflecting recognition of portions of payments from Gilead license agreement.
Focus on Fc reduced formats: Compugen emphasizes the advantages of Fc reduced formats in their programs, citing better safety and efficacy profiles compared to Fc active formats.
AI/ML-powered discovery engine: Compugen's AI/ML-powered discovery engine is delivering innovative research programs, aiming for breakthroughs rather than incremental therapies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Safety concerns with Fc active anti-TIGIT antibodies: High rates of discontinuation due to adverse events in Phase II and Phase III trials, impacting treatment administration and outcomes.
Dependence on Fc reduced anti-TIGIT programs: Success of COM902 and other Fc reduced programs is contingent on positive data readouts, with key results not expected until 2026.
Financial sustainability: Cash runway is projected only until Q3 2027, with limited revenue generation and reliance on milestone payments and royalties.
Regulatory and clinical trial risks: Ongoing trials like MAIA-ovarian and GS-0321 face uncertainties in achieving positive outcomes and regulatory approvals.
Market competition: Compugen's success depends on differentiation in a competitive market, particularly against other Fc reduced anti-TIGIT programs.
Partnership reliance: Significant reliance on partnerships with AstraZeneca and Gilead for milestone payments and royalties, which are subject to their success in clinical trials.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fc reduced anti-TIGIT programs: COM902 is one of the only two clinical-stage Fc reduced anti-TIGIT monoclonal antibodies currently in development. Positive Phase III data from Arcus/Gilead with the only other known Fc reduced anti-TIGIT monoclonal antibody is expected in 2026, which could act as a catalyst for COM902.
Rilvegostomig (Rilve): AstraZeneca's Fc reduced anti-PD-1 TIGIT bispecific, derived from COM902, has a potential commercial opportunity with a non-risk-adjusted peak year revenue target of over $5 billion. AstraZeneca is conducting 11 Phase III trials across various cancers, aiming for Rilve to replace PD-1/PD-L1 therapies and serve as a backbone for future combination treatments.
COM701 (Fc-reduced PVRIG): The ongoing MAIA-ovarian platform trial is evaluating COM701 as maintenance therapy in platinum-sensitive ovarian cancer. Interim analysis is expected in Q1 2027, with potential to address significant unmet needs in this area.
GS-0321 (anti-IL-18 binding protein antibody): Licensed to Gilead, this program represents a novel approach to cancer treatment. Compugen is eligible for $758 million in milestone payments and single-digit to low double-digit tiered royalties. The Phase I trial is progressing as planned.
Cash runway and financial outlook: The company has a cash runway expected to fund operations into Q3 2027, supporting the progression of COM701, GS-0321, and early-stage pipeline investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the extension of the MAIA interim analysis timeline from the second half of 2026 to the first quarter of 2027?
A:The extension is due to factors such as site openings, enrollment rates, and the accumulation of events in the trial. Opening academic centers, including U.S. and French sites, took longer than expected, but most are now open. The company anticipates aggressive enrollment rates and has cash runway into Q3 2027 to support the trial.
Q:What is the company's perspective on the upcoming Arcus/Gilead TIGIT trial readout in gastric cancer?
A:The company views the trial as significant for validating Fc-reduced TIGIT antibodies. If successful, it supports their hypothesis, but even if it fails, other trials and advantages of their bispecific Rilvego, such as cooperative binding and regulatory benefits, provide confidence in their approach.
Q:What internal threshold or bar is the company looking for in the MAIA-ovarian interim update regarding efficacy?
A:The trial aims to determine the magnitude of COM701's effect size. An improvement of up to 3 months above placebo would be clinically meaningful. The study is exploratory and designed to assess single-agent activity and guide next steps.
Q:Does the company have flexibility to partner COM902 with another company despite licensing it to AstraZeneca?
A:Yes, the company fully owns COM902 and has no restrictions. They can pursue their own trials or partner with another company. They believe upcoming readouts could generate significant interest in COM902.
Q:How does the tolerability profile of COM701 influence its potential use in combination therapies?
A:COM701 is extremely well-tolerated as a monotherapy, with no discontinuations due to adverse events. In combination therapies, grade 3 adverse events align with the frequency seen in nivolumab and pembrolizumab labels. Its tolerability makes it suitable for monotherapy or combination with standard care or novel agents.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the specific internal threshold for efficacy in the MAIA-ovarian trial, using vague language about 'totality of the data' and 'next best steps' without detailing precise metrics or criteria.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC antibody
ARCAGY GINECO
Arcus Gilead
AstraZeneca Fc
AstraZeneca ambition
AstraZeneca nonrisk
Berlin analysis
ESMO
Fc TIGITs
Fc format
Fc monoclonal
Fc program
III trial
MAIA platform
Phase II
Phase III
President CEO
antibody approach
cell depletion
checkpoint
conviction
cytokine biology
development program
discontinuation
disease
drug development
effector cell
example
monoclonal antibody
need
pioneer
rate
regs
science
today President
value driver
CGEN Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Unknown5-18
The earnings call summary presents a mixed picture. On one hand, there is a 15% revenue increase and a 10% improvement in net loss, which are positive indicators. However, the lack of discussion on operational updates and strategic initiatives, coupled with risks related to cash management and clinical timelines, introduces uncertainty. The neutral sentiment reflects the balance between financial performance improvements and potential risks, with no strong catalysts to drive a significant stock price change.
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call reveals strong financial performance, with significant revenue growth and a net profit turnaround due to strategic partnerships with AstraZeneca and Gilead. The cash runway supports ongoing projects, and milestone payments are lined up. Despite some uncertainties in timelines, the strategic partnerships and potential in the oncology field are promising. Analysts' questions highlight interest in future milestones and expansions, suggesting confidence in the company's direction. The positive financial results and strategic developments suggest a positive impact on stock price.
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call reveals significant challenges: declining revenues, a shift from profit to loss, and reliance on partnerships and milestone payments. Safety concerns with anti-TIGIT antibodies and competition in the market add risks. The Q&A section highlights uncertainties in trial timelines and outcomes, further dampening sentiment. Despite potential opportunities with COM902 and a cash runway until 2027, the overall financial and strategic outlook suggests a negative market reaction.
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents several concerns: declining revenue and increased net loss, reliance on milestone payments, and negative market sentiment in the TIGIT space. The Q&A section highlighted management's reluctance to provide details, adding uncertainty. Despite a solid cash balance, the financial outlook is weak, with decreased revenue and increased competition in the ovarian cancer treatment market. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
CGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
